Osimertinib, a potent EGFR inhibitor, competitively binds to the ATP site of the tyrosine kinase domain of EGFR, inhibits EGFR autophosphorylation, blocks the cell cycle and promotes apoptosis of tumor cells (Leonetti et al., 2019). Here, EGFR is linked to neoplasm.